

Date: 12th March 2026
Ref: CORP 25/26 - 252

Dear xxx

Freedom of Information request: Treatment of Waldenström Macroglobulinaemia (WM) & Marginal Zone Lymphoma (MZL) (CORP 25/26 – 252)

Thank you for your request for information which the Trust received on 30th January 2026. We apologise for the delay in response.

Your Request:

- Does your Trust treat patients for the two following conditions?
Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)
Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)

If yes:

1a. How many patients did the Trust treat in calendar year 2025 (January to December) for each of the below conditions?

- Waldenström macroglobulinaemia (WM)**
Marginal zone lymphoma (MZL)

1b. Are there any ongoing clinical trials running at the Trust for each of the below conditions? Please can you advise on any details available on the clinical trials.

- Waldenström macroglobulinaemia (WM)**
Marginal zone lymphoma (MZL)

Please skip 1c to question 2 and 3.


If no:

1c. Which Trust(s) does the Trust refer patients onto for treatment for each of the above conditions?

2. How many patients (and new patients* if possible) received treatment for Waldenström macroglobulinaemia (WM) in the period 1st July 2025 to 31st December 2025?

Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)		
Regimen	Total Patients	New Patients*
Fludarabine, cyclophosphamide and rituximab (Known as FCR)		
Bendamustine in combination with rituximab (Known as BR)		
Ibrutinib		

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.





Ibrutinib in combination with rituximab		
Zanubrutinib		
Acalabrutinib		
Chemotherapy (Other than the listed regimens)		
Wait and watch - no active treatment and monitoring only		
Any other treatment (Other than the listed regimens)		

*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

3. How many patients (and new patients* if possible) received treatment for Marginal zone lymphoma (MZL) in the period 1st July 2025 to 31st December 2025?

Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)		
Regimen	Total Patients	New Patients*
Bendamustine in combination with rituximab (Known as BR)		
Chlorambucil in combination with rituximab (Known as CR)		
R CVP (Rituximab + cyclophosphamide + vincristine + prednisolone)		
R CHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)		
Zanubrutinib		
Stem Cell Transplant		
Wait and watch - no active treatment and monitoring only		
Any other treatment (Other than the listed regimens)		

*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

Please find the Trust's response below:


Caveat for the data supplied: Relies on clinical coding data. VCS codes all admitted patient care which includes ordinary admissions, daycases and regular day attenders. We do not code outpatient attendances or ward attenders.

1. Does your Trust treat patients for the two following conditions?

Waldenström macroglobulinaemia (WM) (ICD-10 C88.0) - yes

Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4) - yes

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



1a. How many patients did the Trust treat in calendar year 2025 (January to December) for each of the below conditions?

Waldenström macroglobulinaemia (WM) - 0

Marginal zone lymphoma (MZL) - 21

1b. Are there any ongoing clinical trials running at the Trust for each of the below conditions? Please can you advise on any details available on the clinical trials.

Waldenström macroglobulinaemia (WM) - None

Marginal zone lymphoma (MZL) - None

2. How many patients (and new patients* if possible) received treatment for Waldenström macroglobulinaemia (WM) in the period 1st July 2025 to 31st December 2025?


Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)		
Regimen	Total Patients	New Patients*
Fludarabine, cyclophosphamide and rituximab (Known as FCR)	0	0
Bendamustine in combination with rituximab (Known as BR)	0	0
Ibrutinib	0	0
Ibrutinib in combination with rituximab	0	0
Zanubrutinib	0	0
Acalabrutinib	0	0
Chemotherapy (Other than the listed regimens)	0	0
Wait and watch - no active treatment and monitoring only	0	0
Any other treatment (Other than the listed regimens)	0	0

*Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

3. How many patients (and new patients* if possible) received treatment for Marginal zone lymphoma (MZL) in the period 1st July 2025 to 31st December 2025?

Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)		
Regimen	Total Patients	New Patients*
Bendamustine in combination with rituximab (Known as BR)	0	0
Chlorambucil in combination with rituximab (Known as CR)	0	0
R CVP (Rituximab + cyclophosphamide + vincristine + prednisolone)	0	0
R CHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)	0	0

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Zanubrutinib	0	0
Stem Cell Transplant	N/A	N/A
Wait and watch - no active treatment and monitoring only	Unable to determine from data	Unable to determine from data
Any other treatment (Other than the listed regimens)	<6	<6

***Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.**

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.


You should forward your complaint to:

Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales
2nd Floor,
Churchill House,
Churchill Way,
Cardiff,
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Yours sincerely

**Non Gwilym
Interim Director of Corporate Governance**

Velindre University NHS Trust
2 Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.

